Tarsons Products Limited has released its audited financial results for the quarter and financial year ended March 31, 2026. The company reported a consolidated revenue of ₹423 crores for FY26, reflecting an 8% growth compared to the previous year. The domestic business demonstrated healthy growth, while exports faced challenges due to geopolitical situations affecting transit times and container availability in the Middle East during Q4FY26.

Financial Highlights

The company’s operational performance remained resilient during the fiscal year. Margins in Q4FY26 were impacted by increased raw material prices and expenses related to new facilities. Additionally, Profit After Tax (PAT) was affected by higher depreciation and finance costs associated with the capitalization of new facilities at Panchla and Amta, with revenues from these facilities expected to commence from FY27.

Adjusted Cash PAT for FY26 stood at ₹112 crores, representing a strong 21% year-on-year growth. The company noted that PAT for FY26 was adjusted for a one-time expense of ₹1.3 crores pertaining to the impact of New Labour Codes effective November 21, 2025.

Operational and Strategic Outlook

Management commentary highlighted that the Panchla and Amta facilities have started commercial supplies, with full commissioning expected by H1FY27. The company believes these new capacities and an expanded product portfolio will accelerate growth by onboarding new customers and scaling the export business.

Tarsons remains committed to investing through the current down cycle to strengthen capacities. The company continues to focus on expanding its manufacturing footprint and enhancing its product range in the cell culture and robotic handled consumables segments. The investor presentation has been uploaded to the company’s official website.

Tarsons Products Limited has announced a key senior management appointment, naming Mr. Mani Kalyan Dusi as Head-Revenue (India & APAC) in the Senior Management Personnel category. The appointment, disclosed to stock exchanges on April 14, 2026, under Regulation 30 of SEBI Listing Regulations, reflects the company's strategic focus on strengthening its leadership team in key growth markets.

Appointment Details and Timeline

The Board of Directors approved Mr. Dusi's appointment based on the recommendation of the Nomination & Remuneration Committee. He is expected to join the company on or before May 20, 2026, taking on the critical role of driving revenue operations across India and the Asia-Pacific region.

Professional Background and Expertise

Mr. Mani Kalyan Dusi brings over 18 years of extensive experience in the life sciences, pharmaceuticals, and academic sectors across the APAC region. His professional expertise encompasses commercial leadership, strategic marketing, go-to-market strategies, and P&L management, with a demonstrated track record of driving business growth and operational excellence.

Currently serving as Associate Director and Head – Commercial Enablement (APAC) at Merck Life Science, he leads regional strategy and business development initiatives. His career includes key leadership roles at both Merck Life Science and Thermo-Fisher Scientific, where he successfully managed large portfolios, led cross-functional teams, and strengthened customer-centric innovation and market expansion efforts.

Key Qualifications and Achievements

Mr. Dusi is recognized for his data-driven approach, digital enablement capabilities, and ability to build high-performing teams. His professional accomplishments include:

• Receipt of the AAA Award for marketing leadership at Merck
• Active contribution to diversity, equity, and inclusion (DEI) initiatives
• M.Sc. in Biochemistry (University First Rank) from Andhra University
• Executive leadership education completion at INSEAD

Strategic Implications

The appointment of Mr. Dusi as Head-Revenue for India & APAC underscores Tarsons Products' commitment to strengthening its commercial operations in key growth markets. His extensive experience in the life sciences sector and proven expertise in regional strategy development align with the company's operational focus in laboratory and scientific equipment manufacturing.

The disclosure was made in compliance with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, ensuring transparency in senior management changes for stakeholders and regulatory authorities.